Related Experiment Video
Updated: Aug 9, 2025
09:58
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
3.6K
Integrating metabolomics and lipidomics revealed a decrease in plasma fatty acids but an increase in triglycerides in
Hong-Li Guo1, Wei-Jun Wang2, Na Dong3
1Department of Pharmacy, Pharmaceutical Sciences Research Center, Children's Hospital of Nanjing Medical University, Nanjing, China.
Epilepsia Open
|February 22, 2023
Summary
Drug-resistant epilepsy in children may involve altered fatty acid metabolism. This study found differences in fatty acids and lipids in non-responders to valproic acid therapy, suggesting new treatment avenues.
Area of Science:
- Biochemistry
- Metabolomics
- Pediatric Neurology
Background:
- Drug-resistant epilepsy (DRE) in children presents significant management challenges.
- Underlying mechanisms for DRE remain largely unknown.
- Valproic acid (VPA) is a common antiepileptic drug, but its efficacy varies.
Purpose of the Study:
- To investigate the association between fatty acids (FAs) and lipid profiles with VPA treatment resistance in pediatric epilepsy.
- To identify potential metabolic biomarkers for DRE.
Main Methods:
- Retrospective cohort study of pediatric patients undergoing VPA therapy.
- Plasma samples analyzed using non-targeted metabolomics and lipidomics.
- Comparison of metabolic and lipid profiles between VPA responders and non-responders.
Main Results:
- Significant differences in FAs, glycerophospholipids, and triglycerides (TG) between responder and non-responder groups.
- Elevated glucose and 2-oxoglutarate, decreased citric acid and L-thyroxine in non-responders.
- Key metabolic pathways identified include unsaturated FA biosynthesis and linoleic acid metabolism.
Conclusions:
- Alterations in FA and lipid metabolism are associated with medically intractable epilepsy in children.
- These findings suggest a role for energy metabolism dysregulation in DRE.
- Targeting FA metabolism, potentially through ketogenic diets or FA supplementation, may offer therapeutic strategies for DRE.
More Related Videos
Related Concept Videos
01:24Epilepsy and Seizures: Overview
238
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
238
01:24Overview of Lipid Metabolism
2.0K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.0K
01:14Antiepileptic Drugs: Glutamate Antagonists
457
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
457
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
391
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
391